{
  "input": {
    "mode": "revise",
    "query": {
      "entity": "Generalised pustular psoriasis",
      "relation": "indication"
    },
    "tegraph_snapshot": {
      "nodes": [
        {
          "id": "drug_acitretin",
          "type": "Drug",
          "label": "Acitretin",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_adalimumab",
          "type": "Drug",
          "label": "Adalimumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_apremilast",
          "type": "Drug",
          "label": "Apremilast",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_bimekizumab",
          "type": "Drug",
          "label": "Bimekizumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_brodalumab",
          "type": "Drug",
          "label": "Brodalumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_cyclosporine",
          "type": "Drug",
          "label": "Cyclosporine",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_etanercept",
          "type": "Drug",
          "label": "Etanercept",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_ixekizumab",
          "type": "Drug",
          "label": "Ixekizumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_methotrexate",
          "type": "Drug",
          "label": "Methotrexate",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_secukinumab",
          "type": "Drug",
          "label": "Secukinumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_tazarotene",
          "type": "Drug",
          "label": "Tazarotene",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_ustekinumab",
          "type": "Drug",
          "label": "Ustekinumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "d_generalised_pustular_psoriasis",
          "type": "Disease",
          "label": "Generalised pustular psoriasis",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "target_immune_response",
          "type": "Target",
          "label": "Immune Response",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "pathway_inflammatory_response",
          "type": "Pathway",
          "label": "Inflammatory Response Pathway",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "phenotype_symptomatic_relief",
          "type": "Phenotype",
          "label": "Symptomatic Relief",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "phenotype_skin_remission",
          "type": "Phenotype",
          "label": "Skin Remission",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_ot_acitretin",
          "type": "Target",
          "label": "Acitretin Off-Target",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_rp_acitretin",
          "type": "Pathway",
          "label": "Acitretin Risk Pathway",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_adv_acitretin",
          "type": "Phenotype",
          "label": "Adverse Effects of Acitretin",
          "attrs": {
            "agent": "Skeptic"
          }
        }
      ],
      "edges": [
        {
          "source": "drug_acitretin",
          "target": "target_immune_response",
          "relation": "acts_on",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "常用治疗在免疫调节上有效"
        },
        {
          "source": "drug_adalimumab",
          "target": "target_immune_response",
          "relation": "acts_on",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "靶向 TNF-α 的治疗策略"
        },
        {
          "source": "drug_apremilast",
          "target": "target_immune_response",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "抑制炎症通路的机制"
        },
        {
          "source": "drug_bimekizumab",
          "target": "target_immune_response",
          "relation": "acts_on",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "IL-17靶向作用"
        },
        {
          "source": "drug_brodalumab",
          "target": "target_immune_response",
          "relation": "acts_on",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "IL-17A拮抗剂"
        },
        {
          "source": "drug_cyclosporine",
          "target": "target_immune_response",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "免疫抑制机制支持"
        },
        {
          "source": "drug_etanercept",
          "target": "target_immune_response",
          "relation": "acts_on",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "抑制炎症反应"
        },
        {
          "source": "drug_ixekizumab",
          "target": "target_immune_response",
          "relation": "acts_on",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "IL-17E 的抵抗并促进重建"
        },
        {
          "source": "drug_methotrexate",
          "target": "target_immune_response",
          "relation": "acts_on",
          "weight": 0.65,
          "agent": "Proponent",
          "rationale": "作为传统治疗药物的有效性"
        },
        {
          "source": "drug_secukinumab",
          "target": "target_immune_response",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "针对 IL-17A 的特异性干预"
        },
        {
          "source": "drug_tazarotene",
          "target": "target_immune_response",
          "relation": "acts_on",
          "weight": 0.55,
          "agent": "Proponent",
          "rationale": "调控分化的机制"
        },
        {
          "source": "drug_ustekinumab",
          "target": "target_immune_response",
          "relation": "acts_on",
          "weight": 0.6,
          "agent": "Proponent",
          "rationale": "靶向 IL-12/23 的选择性"
        },
        {
          "source": "target_immune_response",
          "target": "pathway_inflammatory_response",
          "relation": "involved_in",
          "weight": 0.9,
          "agent": "Proponent",
          "rationale": "支持的通路连接"
        },
        {
          "source": "pathway_inflammatory_response",
          "target": "d_generalised_pustular_psoriasis",
          "relation": "causes",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "与通路在病理过程中的一致性"
        },
        {
          "source": "drug_acitretin",
          "target": "phenotype_symptomatic_relief",
          "relation": "supports",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "已知的临床表现改善"
        },
        {
          "source": "drug_adalimumab",
          "target": "phenotype_skin_remission",
          "relation": "supports",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "有效性证据强"
        },
        {
          "source": "drug_apremilast",
          "target": "phenotype_symptomatic_relief",
          "relation": "supports",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "机制的有效性总结"
        },
        {
          "source": "drug_bimekizumab",
          "target": "phenotype_skin_remission",
          "relation": "supports",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "靶向的有效性"
        },
        {
          "source": "drug_brodalumab",
          "target": "phenotype_symptomatic_relief",
          "relation": "supports",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "支持的临床证据"
        },
        {
          "source": "drug_cyclosporine",
          "target": "phenotype_symptomatic_relief",
          "relation": "supports",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "提高患者群体的好转率"
        },
        {
          "source": "drug_etanercept",
          "target": "phenotype_skin_remission",
          "relation": "supports",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "发挥快速生效"
        },
        {
          "source": "drug_ixekizumab",
          "target": "phenotype_skin_remission",
          "relation": "supports",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "针对于根据临床效果获得改善"
        },
        {
          "source": "drug_methotrexate",
          "target": "phenotype_symptomatic_relief",
          "relation": "supports",
          "weight": 0.65,
          "agent": "Proponent",
          "rationale": "已知的改善作用"
        },
        {
          "source": "drug_secukinumab",
          "target": "phenotype_skin_remission",
          "relation": "supports",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "可期待的病理改善"
        },
        {
          "source": "drug_tazarotene",
          "target": "phenotype_symptomatic_relief",
          "relation": "supports",
          "weight": 0.55,
          "agent": "Proponent",
          "rationale": "局部疗法已知效果"
        },
        {
          "source": "drug_ustekinumab",
          "target": "phenotype_skin_remission",
          "relation": "supports",
          "weight": 0.6,
          "agent": "Proponent",
          "rationale": "支持慢性病例治疗的有效性"
        },
        {
          "source": "drug_acitretin",
          "target": "n_ot_acitretin",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "潜在的旁路作用导致不良反应"
        },
        {
          "source": "n_ot_acitretin",
          "target": "n_rp_acitretin",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能通过非靶向途径导致风险"
        },
        {
          "source": "n_rp_acitretin",
          "target": "n_adv_acitretin",
          "relation": "causes",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "导致不良表型"
        },
        {
          "source": "n_adv_acitretin",
          "target": "H1",
          "relation": "refutes",
          "weight": 0.8,
          "agent": "Skeptic",
          "rationale": "若存在此风险，则抵消潜在疗效"
        }
      ],
      "round_index": 3
    },
    "history": {
      "round": 3,
      "last_scores": [
        {
          "hypothesis_id": "H1",
          "score": 0.52,
          "components": {
            "mechanism_fit": 0.6,
            "class_prior": 0.5,
            "pk_pd_feasibility": 0.5,
            "indication_plausibility": 0.6,
            "safety_risk": 0.2,
            "graph_bonus": 0.1,
            "conflict_penalty": 0.1
          },
          "graph_signals": {
            "support_weight": 4.55,
            "contradiction_weight": 0.8,
            "mechanistic_connectivity": true,
            "path_disjointness": 2,
            "conflict_hotspots": [
              {
                "topic": "Acitretin Safety",
                "pro": [
                  "n_adv_acitretin"
                ],
                "con": [
                  "H1"
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "Acitretin 可作用于免疫反应，与炎症通路相关"
            ],
            "safety_risk": [
              "潜在的旁路作用对安全性产生重要影响"
            ]
          },
          "confidence": "medium",
          "uncertainties": [
            "需进一步验证Acitretin在该病症中的疗效"
          ]
        },
        {
          "hypothesis_id": "H2",
          "score": 0.78,
          "components": {
            "mechanism_fit": 0.9,
            "class_prior": 0.7,
            "pk_pd_feasibility": 0.6,
            "indication_plausibility": 0.8,
            "safety_risk": 0.2,
            "graph_bonus": 0.15,
            "conflict_penalty": 0.1
          },
          "graph_signals": {
            "support_weight": 5.25,
            "contradiction_weight": 0.8,
            "mechanistic_connectivity": true,
            "path_disjointness": 2,
            "conflict_hotspots": []
          },
          "rationales": {
            "mechanism_fit": [
              "Adalimumab 有针对 TNF-α 的有效机制"
            ],
            "indication_plausibility": [
              "临床数据支持Adalimumab在特定病症中的疗效"
            ]
          },
          "confidence": "high",
          "uncertainties": []
        },
        {
          "hypothesis_id": "H3",
          "score": 0.61,
          "components": {
            "mechanism_fit": 0.7,
            "class_prior": 0.5,
            "pk_pd_feasibility": 0.5,
            "indication_plausibility": 0.65,
            "safety_risk": 0.2,
            "graph_bonus": 0.1,
            "conflict_penalty": 0.05
          },
          "graph_signals": {
            "support_weight": 3.55,
            "contradiction_weight": 0.0,
            "mechanistic_connectivity": true,
            "path_disjointness": 2,
            "conflict_hotspots": []
          },
          "rationales": {
            "mechanism_fit": [
              "Apremilast 通过抑制炎症反应机制发挥作用"
            ],
            "indication_plausibility": [
              "有临床研究支持其在炎症性皮肤病中的应用"
            ]
          },
          "confidence": "medium",
          "uncertainties": []
        },
        {
          "hypothesis_id": "H4",
          "score": 0.68,
          "components": {
            "mechanism_fit": 0.8,
            "class_prior": 0.6,
            "pk_pd_feasibility": 0.5,
            "indication_plausibility": 0.65,
            "safety_risk": 0.2,
            "graph_bonus": 0.15,
            "conflict_penalty": 0.1
          },
          "graph_signals": {
            "support_weight": 4.25,
            "contradiction_weight": 0.0,
            "mechanistic_connectivity": true,
            "path_disjointness": 2,
            "conflict_hotspots": []
          },
          "rationales": {
            "mechanism_fit": [
              "Bimekizumab 的 IL-17 促进抗炎功效"
            ],
            "indication_plausibility": [
              "有临床试验数据支持其效果"
            ]
          },
          "confidence": "medium",
          "uncertainties": []
        },
        {
          "hypothesis_id": "H5",
          "score": 0.65,
          "components": {
            "mechanism_fit": 0.75,
            "class_prior": 0.6,
            "pk_pd_feasibility": 0.5,
            "indication_plausibility": 0.6,
            "safety_risk": 0.2,
            "graph_bonus": 0.1,
            "conflict_penalty": 0.0
          },
          "graph_signals": {
            "support_weight": 4.0,
            "contradiction_weight": 0.0,
            "mechanistic_connectivity": true,
            "path_disjointness": 2,
            "conflict_hotspots": []
          },
          "rationales": {
            "mechanism_fit": [
              "Brodalumab 能有效针对 IL-17A"
            ],
            "indication_plausibility": [
              "有研究支持其在相关疾病中的应用"
            ]
          },
          "confidence": "medium",
          "uncertainties": []
        },
        {
          "hypothesis_id": "H6",
          "score": 0.55,
          "components": {
            "mechanism_fit": 0.5,
            "class_prior": 0.5,
            "pk_pd_feasibility": 0.5,
            "indication_plausibility": 0.6,
            "safety_risk": 0.2,
            "graph_bonus": 0.1,
            "conflict_penalty": 0.0
          },
          "graph_signals": {
            "support_weight": 3.0,
            "contradiction_weight": 0.0,
            "mechanistic_connectivity": true,
            "path_disjointness": 2,
            "conflict_hotspots": []
          },
          "rationales": {
            "mechanism_fit": [
              "Cyclosporine 的免疫抑制作用"
            ],
            "indication_plausibility": [
              "对于某些患者可能有效，但疗效不一致"
            ]
          },
          "confidence": "medium",
          "uncertainties": []
        },
        {
          "hypothesis_id": "H7",
          "score": 0.71,
          "components": {
            "mechanism_fit": 0.85,
            "class_prior": 0.6,
            "pk_pd_feasibility": 0.6,
            "indication_plausibility": 0.7,
            "safety_risk": 0.2,
            "graph_bonus": 0.1,
            "conflict_penalty": 0.0
          },
          "graph_signals": {
            "support_weight": 4.25,
            "contradiction_weight": 0.0,
            "mechanistic_connectivity": true,
            "path_disjointness": 2,
            "conflict_hotspots": []
          },
          "rationales": {
            "mechanism_fit": [
              "Etanercept 可有效抑制炎症"
            ],
            "indication_plausibility": [
              "在PSA中显示出效果"
            ]
          },
          "confidence": "medium",
          "uncertainties": []
        },
        {
          "hypothesis_id": "H8",
          "score": 0.67,
          "components": {
            "mechanism_fit": 0.75,
            "class_prior": 0.6,
            "pk_pd_feasibility": 0.5,
            "indication_plausibility": 0.65,
            "safety_risk": 0.2,
            "graph_bonus": 0.1,
            "conflict_penalty": 0.0
          },
          "graph_signals": {
            "support_weight": 4.0,
            "contradiction_weight": 0.0,
            "mechanistic_connectivity": true,
            "path_disjointness": 2,
            "conflict_hotspots": []
          },
          "rationales": {
            "mechanism_fit": [
              "Ixekizumab 有针对性的作用于 IL-17E"
            ],
            "indication_plausibility": [
              "针对皮肤病有支持性的临床数据"
            ]
          },
          "confidence": "medium",
          "uncertainties": []
        },
        {
          "hypothesis_id": "H9",
          "score": 0.6,
          "components": {
            "mechanism_fit": 0.55,
            "class_prior": 0.5,
            "pk_pd_feasibility": 0.5,
            "indication_plausibility": 0.6,
            "safety_risk": 0.2,
            "graph_bonus": 0.1,
            "conflict_penalty": 0.0
          },
          "graph_signals": {
            "support_weight": 3.5,
            "contradiction_weight": 0.0,
            "mechanistic_connectivity": true,
            "path_disjointness": 2,
            "conflict_hotspots": []
          },
          "rationales": {
            "mechanism_fit": [
              "Methotrexate 在慢性炎症条件下有效"
            ],
            "indication_plausibility": [
              "传统药物有基础疗效"
            ]
          },
          "confidence": "medium",
          "uncertainties": []
        },
        {
          "hypothesis_id": "H10",
          "score": 0.64,
          "components": {
            "mechanism_fit": 0.7,
            "class_prior": 0.5,
            "pk_pd_feasibility": 0.5,
            "indication_plausibility": 0.65,
            "safety_risk": 0.2,
            "graph_bonus": 0.1,
            "conflict_penalty": 0.0
          },
          "graph_signals": {
            "support_weight": 3.5,
            "contradiction_weight": 0.0,
            "mechanistic_connectivity": true,
            "path_disjointness": 2,
            "conflict_hotspots": []
          },
          "rationales": {
            "mechanism_fit": [
              "Secukinumab 专门针对 IL-17A"
            ],
            "indication_plausibility": [
              "可期待的效果在临床上有支持"
            ]
          },
          "confidence": "medium",
          "uncertainties": []
        },
        {
          "hypothesis_id": "H11",
          "score": 0.5,
          "components": {
            "mechanism_fit": 0.5,
            "class_prior": 0.5,
            "pk_pd_feasibility": 0.5,
            "indication_plausibility": 0.5,
            "safety_risk": 0.2,
            "graph_bonus": 0.1,
            "conflict_penalty": 0.0
          },
          "graph_signals": {
            "support_weight": 2.5,
            "contradiction_weight": 0.0,
            "mechanistic_connectivity": true,
            "path_disjointness": 2,
            "conflict_hotspots": []
          },
          "rationales": {
            "mechanism_fit": [
              "Tazarotene 主要是局部作用"
            ],
            "indication_plausibility": [
              "适用于局部治疗"
            ]
          },
          "confidence": "medium",
          "uncertainties": []
        },
        {
          "hypothesis_id": "H12",
          "score": 0.63,
          "components": {
            "mechanism_fit": 0.6,
            "class_prior": 0.5,
            "pk_pd_feasibility": 0.5,
            "indication_plausibility": 0.65,
            "safety_risk": 0.2,
            "graph_bonus": 0.1,
            "conflict_penalty": 0.0
          },
          "graph_signals": {
            "support_weight": 3.5,
            "contradiction_weight": 0.0,
            "mechanistic_connectivity": true,
            "path_disjointness": 2,
            "conflict_hotspots": []
          },
          "rationales": {
            "mechanism_fit": [
              "Ustekinumab 特异性靶向 IL-12/23"
            ],
            "indication_plausibility": [
              "支持慢性病例的治疗效果"
            ]
          },
          "confidence": "medium",
          "uncertainties": []
        }
      ]
    },
    "thresholds": {
      "stop_delta": 0.03,
      "saturation_ratio": 0.65,
      "weights": {
        "path_disjointness": 1.0
      }
    },
    "ablation_config": {
      "enable_debate": true,
      "enable_skeptic": true,
      "enable_pi_interrupts": true,
      "enable_textual_feedback": true,
      "enable_heuristic_transfer": true,
      "enable_seed_regen": true,
      "weights": {
        "path_disjointness": 1.0
      },
      "mode": "graph"
    }
  },
  "output": {
    "revisions": [
      {
        "hypothesis_id": "H1",
        "graph_actions": [
          {
            "type": "stress_test_safety",
            "topic": "Acitretin Potential Risks",
            "expectation": "若存在不良反应，则在后续评估中降低其支持力度",
            "assignee": "Skeptic"
          },
          {
            "type": "merge_claims",
            "nodes": [
              "n_adv_acitretin",
              "H1"
            ],
            "rationale": "同一药物的多种作用路径需综合考虑，以降低图的复杂性"
          }
        ],
        "debate_focus": [
          "是否考虑药物安全性对疗效的影响",
          "对 Acitretin 的风险与效益平衡的阐述"
        ]
      },
      {
        "hypothesis_id": "H2",
        "graph_actions": [],
        "debate_focus": []
      }
    ],
    "pruned_hypotheses": [],
    "new_subhypotheses": [],
    "seed_request": {
      "should_regenerate": false,
      "reason": "现有假设的机制和效用均已覆盖，安全性及潜在不良效应需进一步验证，未达最佳路径独立性。",
      "n": 4
    }
  }
}